Digest Network Come funziona
Network
/
Società
St
Non verificato

Star Therapeutics

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaSaluteScienza

7 comunicati stampa

Guarda tutti i comunicati
03/11/2025
Industria
Salute
Sanità
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Star Therapeutics to Present Interim Data from Phase 1/2 Multidose Study of VGA039 in von Willebrand disease at ASH Annual Meeting
Fonte
Star Therapeutics
Emittente
Business Wire
1.00
0
30/09/2025
Scienza
Biotecnologia
Farmaceutica
Finanza
Salute
Associazioni/Professionisti
Medicina - Varie
Industria
Star Therapeutics Announces Oversubscribed $125 Million Series D Financing
Fonte
Star Therapeutics
Emittente
Business Wire
1.00
0
06/01/2025
Industria
Scienza
Igiene alimentare
Cardiologia
Biotecnologia
Sanità
Salute
Farmaceutica
Star Therapeutics Receives FDA Fast Track Designation for VGA039 in Von Willebrand Disease (VWD)
Fonte
Star Therapeutics
Emittente
Business Wire
1.00
0
02/01/2025
Eventi
Industria
Biotecnologia
Farmaceutica
Salute
Cardiologia
Star Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Fonte
Star Therapeutics
Emittente
Business Wire
1.00
0
09/12/2024
Eventi
Fiere
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Star Therapeutics Presents Interim Clinical Data for VGA039 in Patients with Von Willebrand Disease (VWD) at ASH 2024
Fonte
Star Therapeutics
Emittente
Business Wire
1.00
0
09/12/2024
Fiere
Eventi
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Star Therapeutics Presents Interim Clinical Data for VGA039 in Patients with Von Willebrand Disease (VWD) at ASH 2024
Fonte
Star Therapeutics
Emittente
Business Wire
1.00
0
26/06/2024
Eventi
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Star Therapeutics Presents Clinical Data for VGA039, a Subcutaneous Therapy for the Treatment of Von Willebrand Disease (VWD)
Fonte
Star Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0